ArticleOncology letters2025
Preoperative peripheral blood routine indicators as predictors of prognosis and diagnosis in glioma under the 2021 World Health Organization classification.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple hematological indicators have been shown to be associated with the prediction and prognosis of gliomas. The present study aimed to explore the value of 22 preoperative peripheral blood routine indicators in the diagnosis and prognosis prediction of glioma. Patients with glioma were grouped according to the 2021 World Health Organization (WHO) guidelines for glioma. The correlations among preoperative peripheral blood routine indicators in all patients with glioma were assessed using Spearman's rank correlation analysis. The relationships between these indicators and glioma molecular subtypes were evaluated using ANOVA, independent samples t-test and logistic regression analysis. Analysis of prognosis prediction was conducted using multivariate Cox regression. Based on the WHO 2021 guidelines, patients with glioma were classified into 92 cases of astrocytoma, 77 cases of oligodendroglioma and 402 cases of glioblastoma. Among 22 routine blood indicators, 10 low-correlation indicators were identified, 9 of which demonstrated significant value for the diagnosis of glioma. Among them, the neutrophil percentage (NEUT%) showed a notable predictive power in glioma molecular subtypes classification. In the study of overall survival (OS) prediction in patients with glioma, 6 biomarkers were found to be significantly associated with OS. Through statistical analysis, 4 independent biomarkers were selected to construct a multivariable Cox regression model. However, in the regression model, NEUT% was identified as the sole statistically significant biomarker. Despite its statistical significance, the results indicated that NEUT% had limited effectiveness in predicting OS in patients with glioma. Certain preoperative blood indicators had significant predictive value for glioma diagnosis, with NEUT% emerging as a key biomarker for predicting the presence of glioma. For prognosis, although NEUT% showed a modest effect size, it was significantly associated with poor outcomes in patients with glioma. Monitoring preoperative NEUT% levels is therefore clinically important for glioma diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.